XML 21 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Statements of Changes in Stockholders' (Deficit) Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2023   $ 57 $ 154,490,596   $ (145,491,559) $ 8,999,094
Balance at the beginning (in shares) at Dec. 31, 2023   569,409        
Issuance of common stock in At the Market offering [1]   $ 7 6,047,362     6,047,369
Issuance of common stock in At the Market offering (in shares) [1]   70,381        
Issuance of common stock as consideration for licensing agreement [2]   $ 1 436,808     436,809
Issuance of common stock as consideration for licensing agreement (in shares) [2]   7,668        
Issuance of common stock as consideration for reacquisition of licensing agreement [3]   $ 3 2,322,388     2,322,391
Issuance of common stock as consideration for reacquisition of licensing agreement (in shares) [3]   28,742        
Issuance of common stock and warrants in offerings [4]   $ 66 17,011,256     $ 17,011,322
Issuance of common stock and warrants in offerings (in shares)   653,493 [4]       653,493
Issuance of common stock from exercise of warrants   $ 15 1,208     $ 1,223
Issuance of common stock from exercise of warrants (in shares)   152,905        
Warrant modification and additional warrants - incremental value [5]     2,868,000     2,868,000
Warrants issued in consideration for debt modification [6]     (2,868,000)     (2,868,000)
Issuance of common stock as consideration for modification of loan agreement   $ 2 199,998     200,000
Issuance of common stock as consideration for modification of loan agreement (in shares)   23,771        
Stock-based compensation:            
Amortization of stock option awards     1,454,946     1,454,946
Amortization of restricted stock units     249,327     249,327
Net loss         (49,818,433) (49,818,433)
Balance at the end at Dec. 31, 2024   $ 151 182,213,889   (195,309,992) (13,095,952)
Balance at the end (in shares) at Dec. 31, 2024   1,506,369        
Issuance of preferred stock and warrants in private placement [7] $ 544   49,365,206     49,365,750
Issuance of preferred stock and warrants in private placement (in shares) [7] 5,435,897          
Issuance of common stock in At the Market offering [8]   $ 561 39,357,243     39,357,804
Issuance of common stock in At the Market offering (in shares) [8]   5,607,759        
Issuance of common stock from exercise of warrants [9]   $ 50 3,892,423     3,892,473
Issuance of common stock from exercise of warrants (in shares) [9]   (502,125)        
Induced exercise of stock warrants [10]   $ 19 922,731     922,750
Induced exercise of stock warrants (in shares) [10]   197,118        
Issuance of common stock from the partial conversion of note payable   $ 41 640,295     640,336
Issuance of common stock from the partial conversion of note payable (in shares)   404,820        
Issuance of common stock from the delivery of vested restricted stock units   $ 53 (53)      
Issuance of common stock from the delivery of vested restricted stock units (in shares)   529,297        
Warrant modification and additional warrants - incremental value     858,270     858,270
Shares withheld for employee payroll taxes       $ 253,558   253,558
Shares withheld for employee payroll taxes (in shares)       82,324    
Reverse stock split settlement of fractional shares     (160)     (160)
Reverse stock split settlement of fractional shares (in shares)   (41)        
Stock-based compensation:            
Amortization of stock option awards     533,062     533,062
Amortization of restricted stock units     5,785,548     5,785,548
Issuance of common stock to vendors in consideration for service provided   $ 1 53,401     53,402
Issuance of common stock to vendors in consideration for service provided (in shares)   14,882        
Net loss         (45,314,435) (45,314,435)
Preferred stock dividend ($0.59 per preferred share outstanding)     (1,684,783)     (1,684,783)
Balance at the end at Dec. 31, 2025 $ 544 $ 876 $ 281,937,072 $ (253,558) $ (240,624,427) $ 41,060,507
Balance at the end (in shares) at Dec. 31, 2025 5,435,897 8,762,329        
Treasury stock balance at the end (in shares) at Dec. 31, 2025       82,324   82,324
[1] Includes gross proceeds of $6,234,402 less total issuance costs of $187,033.
[2] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.
[3] Shares issued as partial consideration for reversion of License Agreement with Bausch & Lomb Ireland Limited.
[4] Includes gross proceeds of $19,385,015, less total cash issuance costs of $2,373,693.
[5] Offering includes modification of warrants and additional warrants in the July 2024 offering.
[6] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings are shown on a separate line item for clarity.
[7] Includes gross proceeds of $50,000,000 less total issuance costs of $634,250.
[8] Includes gross proceeds of $40,645,265 less total issuance costs of $1,287,461.
[9] Partial exercise of the Armistice warrants.
[10] Includes gross proceeds of $1,039,206 less total issuance costs of $116,456. Also note that incremental value and non-cash warrant modification and additional warrants issuance costs related to the warrant inducement entered into on January 16, 2025 offset to a zero balance. See Note 13 – Stockholders’ Equity (Deficiency).